BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type
urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have
failed platinum-based chemotherapy.